Full-Time

Senior R&D Project Manager

Posted on 9/3/2025

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$150k - $175k/yr

Pleasanton, CA, USA

In Person

Category
Business & Strategy (1)
Required Skills
SCRUM
Requirements
  • Education: Engineering/Science degree or equivalent required
  • Minimum 8 years total experience; medical device development experience strongly preferred
  • Work location: Pleasanton, CA office
  • Travel: approximately 10%
  • Full time employment
  • Hard Skills: experience with full product development lifecycle for hardware/software/firmware systems; familiarity with FDA submission process, ISO 13485, ISO 14971 and QSR requirements; proficiency in MS Office, Atlassian/JIRA, Monday.com and other project management tools
  • Soft skills: strong facilitation and communication skills across technical and executive audiences; ability to lead cross-functional teams and influence without direct authority; naturally accountable and organized
  • Physical requirements - Must be able to sit for up to 8 hours/day and operate standard office equipment
  • Compliance with relevant county, state, and Federal rules regarding vaccinations
Responsibilities
  • Promote transparency through excellent written and verbal communication skills – routinely provide visibility on project state to team, peers, and Senior Staff, including decisions, dependencies, issues, risks and schedule
  • Develop alignment among contributors and stakeholders on scope, effort, value and ordering of work to achieve program goals. Contributors include engineering, operations, quality, commercial, finance, regulatory and clinical
  • Lead the program. Guide internal and external team members to define outcomes, coordinate efforts, establish metrics and adapt to achieve goals
  • Establish relationships with peers at all levels to promote positive work habits, sharing of work and knowledge
  • Facilitate software, firmware and engineering development through ordering work, defining Done, backlog prioritization, Sprint Planning and Retrospectives
  • Anticipate and aggressively remove obstacles that prevent the team from delivering on goals. Foster communication and decision-making to either persevere forward to change the path
  • Contribute to process improvements and best practices tailored to Calyxo’s culture to develop a best-in-class project management infrastructure
  • Handle abstract development decisions with risk-based decision-making, contingency planning, and tradeoff analyses

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Calyxo raised $40 million in Series F from specialist healthcare investors.
  • CVAC crossed 40,000 kidney stone procedures, strengthening physician referenceability.
  • Funding supports commercial expansion and health-economic evidence generation.

What critics are saying

  • Boston Scientific already owns installed ureteroscopy franchises in most hospitals.
  • A 2024 MAUDE report documented sepsis and death after CVAC use.
  • Calyxo still depends on early evidence; larger studies can narrow differentiation.

What makes Calyxo unique

  • CVAC continuously aspirates stone fragments during and after laser lithotripsy.
  • FDA cleared CVAC in March 2024, lowering regulatory friction.
  • ASPIRE showed superior stone clearance and lower residual stone volume versus URS.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE